{"id":66546,"date":"2026-06-08T12:00:00","date_gmt":"2026-06-08T10:00:00","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/06\/08\/systematic-review-and-meta-analysis-of-anti-interferon-auto-antibodies-in-infectious-diseases\/"},"modified":"2026-06-08T12:00:00","modified_gmt":"2026-06-08T10:00:00","slug":"systematic-review-and-meta-analysis-of-anti-interferon-auto-antibodies-in-infectious-diseases","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/06\/08\/systematic-review-and-meta-analysis-of-anti-interferon-auto-antibodies-in-infectious-diseases\/","title":{"rendered":"Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases"},"content":{"rendered":"<div>\n<p><b>J Clin Immunol<\/b>. 2026 Jun 9. doi: 10.1007\/s10875-026-02038-6. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>PURPOSE: To perform a systematic review and meta-analysis of prevalence and function of anti-interferon auto-antibodies in acute infectious diseases.<\/p>\n<p>METHODS: We performed a search on the following electronic bibliographic databases: Medline, Embase, Web of Science and Cochrane. Eligible studies generated a systematic review and random effects model meta-analysis of pooled seroprevalence and neutralisation status of anti-interferon auto-antibodies in acute infectious diseases.<\/p>\n<p>RESULTS: Thirty-seven studies including 12,629 individuals with SARS-CoV-2 infection were analysed. There are insufficient data for meta-analyses of auto-antibodies in non-SARS-CoV-2 infectious diseases, with crude seroprevalence of auto-antibodies varying widely (0.0-77.0%). The pooled seroprevalence of anti-IFN\u0251 and\/or anti-IFN\u2375 auto-antibodies in individuals with SARS-CoV-2 infection was 14% (95%CI 9-18%, I<sup>2<\/sup> = 92%, [Formula: see text]<sup>2<\/sup> = 0.0151, p &lt; 0.01). Pooled prevalence of neutralising auto-antibodies were slightly lower (12%; 95%CI 8-17%, I<sup>2<\/sup> = 77%, [Formula: see text]<sup>2<\/sup> = 0.0027, p &lt; 0.01). The high heterogeneity may reflect divergent SARS-CoV-2 disease severity across studies, and methodological diversity for measurement and definition of auto-antibody binding and neutralisation. Pooled seroprevalence for anti-IFN\u0251 auto-antibodies in uninfected healthy controls were &lt; 1% (95%CI 0-1%, I<sup>2<\/sup> = 90%, [Formula: see text]<sup>2<\/sup> = 0.0028, p &lt; 0.01).<\/p>\n<p>CONCLUSION: Anti-interferon auto-antibodies may impair immune responses to diverse infections leading to life-threatening disease. These auto-antibodies have not been studied at all in most infectious diseases, most notably for bacterial infection. This study illustrates the urgent need to standardise methodology and reporting of auto-antibodies in the setting of infectious diseases so that the immunopathology and translational impact of these novel biomarkers can be realised.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42260236\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=8102137&amp;ff=20260609005550&amp;v=2.20.0\">42260236<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1007\/s10875-026-02038-6\">10.1007\/s10875-026-02038-6<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Clin Immunol. 2026 Jun 9. doi: 10.1007\/s10875-026-02038-6. Online ahead of print. ABSTRACT PURPOSE: To perform a systematic review and meta-analysis of prevalence and function of anti-interferon auto-antibodies in acute infectious diseases. METHODS: We performed a search on the following electronic bibliographic databases: Medline, Embase, Web of Science and Cochrane. Eligible studies generated a systematic &#8230; <a title=\"Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/08\/systematic-review-and-meta-analysis-of-anti-interferon-auto-antibodies-in-infectious-diseases\/\" aria-label=\"Read more about Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,42],"tags":[],"class_list":["post-66546","post","type-post","status-publish","format-standard","hentry","category-journal-of-clinical-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/66546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=66546"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/66546\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=66546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=66546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=66546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}